11th Annual Meeting DIA Japan 2014

Featured

Want to learn more about 11th Annual Meeting DIA Japan 2014? You've come to the right site!

Continuing-Education

Short Course or Primer

To keep you at the forefront.

2014年11月16日 (日)

#10 HTA 2016? What are the challenges for Japan?:

2014年11月16日 (日)

#1 Basic Introduction for Non-Specialist:

Drug-Drug Interaction and Summary of Change in New Japanese Drug-Drug Interaction Guideline

2014年11月16日 (日)

#2 Next Steps for Content of Company Core Data Sheet Prepared by Western Companies - Part 1:

2014年11月16日 (日)

#3 Action Learning for Six Sigma Analytical Tools Using Real Case Studies:

2014年11月16日 (日)

#4 Coaching as a Diverse Communication Tool Across Functions and Areas:

2014年11月16日 (日)

#5 The Basics of “Investigator Initiated Trial (IIT)” Regulation:

2014年11月16日 (日)

#6 Prediction for Human Pharmacokinetics and Safety Using Systems Pharmacology:

2014年11月16日 (日)

#7 Next Steps for Content of Company Core Data Sheet Prepared by Western Companies - Part 2:

2014年11月16日 (日)

#8 An Introduction to Adaptive Designs:

2014年11月16日 (日)

#10 HTA 2016? What are the challenges for Japan?:

2014年11月16日 (日)

#1 Basic Introduction for Non-Specialist:

Drug-Drug Interaction and Summary of Change in New Japanese Drug-Drug Interaction Guideline

2014年11月16日 (日)

#2 Next Steps for Content of Company Core Data Sheet Prepared by Western Companies - Part 1:

2014年11月16日 (日)

#3 Action Learning for Six Sigma Analytical Tools Using Real Case Studies:

2014年11月16日 (日)

#4 Coaching as a Diverse Communication Tool Across Functions and Areas:

2014年11月16日 (日)

#5 The Basics of “Investigator Initiated Trial (IIT)” Regulation:

2014年11月16日 (日)

#6 Prediction for Human Pharmacokinetics and Safety Using Systems Pharmacology:

2014年11月16日 (日)

#7 Next Steps for Content of Company Core Data Sheet Prepared by Western Companies - Part 2:

2014年11月16日 (日)

#8 An Introduction to Adaptive Designs:

Hiroshi Watanabe, MD, PHD Vice President
Hamamatsu University School of Medicine, Japan
Kenji Nagaya Project Manager, Clinical Research Center
Nagoya Medical Center, Japan
Kasumi Daidoji, PHD, RPH Associate Director, Clinical Planning & Development Dept., Medical Headquarters
Eisai Company, Ltd., Japan
Hideki Hanaoka, MD, PHD
Chiba University Hospital Clinical Research Center, Japan
Akiko Ikeda, RPH PRIMO, External Researcher/Consultant
National Cancer Center, Japan
Eiji Kajiwara Director, CMC Regulatory Affairs
MSD K.K., Japan
Kazuhiro Kanmuri, PHD Executive Officer, Head of Development Div.
Tanabe Pharma Corporation, Japan
Kazutoshi Maki Chairman
GENEX Partners, Japan
Kana Maruyama Manager, Regulatory Labeling, Regulatory Affairs
Viatris Pharmaceuticals Japan GK, Japan
Koichi Miyazaki, PHD Senior Director, Group IV, Oncology Clinical Development Department
Daiichi Sankyo Co., Ltd., Japan
Motohide Nishi, MBA Japan Site Leader & VP Professional Services
Medidata Solutions K.K., Japan
Junichi Nishino, MSC, RPH Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan
Masayo Oishi, PHD Clinical Pharmacologist, Clinical Pharmacology, Clinical Research
Pfizer Japan Inc., Japan
Satoshi Saeki, MSC Head of Japan Operational Excellence, Medical Affairs, Japan
Astellas Pharma Inc., Japan
Shuji Sumida, MSC, RPH Director
Project Quality and Risk Management, Japan
Satoru Tsuchiya, MSC VP, Global Data Design Office
Sumitomo Pharma Co., Ltd. , Japan
Naoyuki Yabana, PHD Director, Office of In Vitro Diagnostics
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Takeharu Yamanaka, PHD Professor, Department of Biostatics, School of Medicine
Yokohama City University, Japan
Yoshihiko Ono, RPH Regulatory Executive Advisor
MSD K.K., Japan
Junko Sato, PHD Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan